Restrictions lifted on anti-dementia drugs

The review was initiated due to concern that donepezil, rivastigmine, galantamine and memantine were being prescribed for too long without improvement in rates of institutionalisation and death.

Currently the drugs can only be prescribed beyond six months if the patient demonstrates a two-point improvement on the mini-mental state exam (MMSE).

But from 1 May changes to the PBS mean the more than 130,000 Australians with Alzheimer’s disease can continue treatment for as